159 related articles for article (PubMed ID: 32368308)
1. IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape
Hu JQ; Lei BW; Wen D; Ma B; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Li DS; Ji QH; Liao T
J Cancer; 2020; 11(14):4250-4260. PubMed ID: 32368308
[TBL] [Abstract][Full Text] [Related]
2. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
[TBL] [Abstract][Full Text] [Related]
3. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
[TBL] [Abstract][Full Text] [Related]
4. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
[TBL] [Abstract][Full Text] [Related]
5. Cytokine production of papillary thyroid carcinoma coexisting with Hashimoto's thyroiditis.
Shi L; Zhou L; Wang J; Li F; Xie L
Int J Clin Exp Pathol; 2017; 10(9):9567-9574. PubMed ID: 31966833
[TBL] [Abstract][Full Text] [Related]
6. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract][Full Text] [Related]
7. Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis.
Zeng R; Lyu Y; Zhang G; Shou T; Wang K; Niu H; Yan X
Am J Transl Res; 2018; 10(10):3011-3024. PubMed ID: 30416647
[TBL] [Abstract][Full Text] [Related]
8. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
[TBL] [Abstract][Full Text] [Related]
9. Mutation of Hashimoto's Thyroiditis and Papillary Thyroid Carcinoma Related Genes and the Screening of Candidate Genes.
Zhang L; Zhou L; Feng Q; Li Q; Ge M
Front Oncol; 2021; 11():813802. PubMed ID: 34993154
[TBL] [Abstract][Full Text] [Related]
10. Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links.
Sulaieva O; Selezniov O; Shapochka D; Belemets N; Nechay O; Chereshneva Y; Tsomartova D; Ivanova M
Heliyon; 2020 Jan; 6(1):e03077. PubMed ID: 31938743
[TBL] [Abstract][Full Text] [Related]
11. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis.
Stanciu AE; Serdarevic N; Hurduc AE; Stanciu MM
Scand J Clin Lab Invest; 2015 Nov; 75(7):539-48. PubMed ID: 26305420
[TBL] [Abstract][Full Text] [Related]
12. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
13. Clonal Distribution and Intratumor Heterogeneity of the TCR Repertoire in Papillary Thyroid Cancer With or Without Coexistent Hashimoto's Thyroiditis.
Cui L; Zhang C; Ding H; Feng D; Huang H; Lu Z; Liu B
Front Immunol; 2022; 13():821601. PubMed ID: 35720279
[TBL] [Abstract][Full Text] [Related]
14. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
15. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.
Liu Y; Yun X; Gao M; Yu Y; Li X
Clin Transl Oncol; 2015 Apr; 17(4):274-80. PubMed ID: 25387566
[TBL] [Abstract][Full Text] [Related]
16. Expression of NIS, VEGF-A and Thyroid Autoantibody in Papillary Thyroid Carcinoma with or without Hashimoto's Disease.
Ma Y; He J; Shen N; Guo R
ORL J Otorhinolaryngol Relat Spec; 2019; 81(5-6):281-286. PubMed ID: 31480047
[TBL] [Abstract][Full Text] [Related]
17. Significance of DMBT1 in Papillary Thyroid Carcinoma Concurrent With Hashimoto's Thyroiditis.
Gan XX; Li YY; Li SJ; Mo SS; Feng JH; Shen F; Cai WS; Lai YQ; Xu B
Front Oncol; 2021; 11():680873. PubMed ID: 34422633
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
19. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
20. Intercellular adhesion molecule 1 is a sensitive and diagnostically useful immunohistochemical marker of papillary thyroid cancer (PTC) and of PTC-like nuclear alterations in Hashimoto's thyroiditis.
Zhang KE; Ge SJ; Lin XY; Lv BB; Cao ZX; Li JM; Xu JW; Wang QX
Oncol Lett; 2016 Mar; 11(3):1722-1730. PubMed ID: 26998068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
